Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $8.8 million.

  • Serina Therapeutics' Total Current Liabilities fell 3496.37% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year decrease of 3496.37%. This contributed to the annual value of $2.4 million for FY2024, which is 6744.52% up from last year.
  • Latest data reveals that Serina Therapeutics reported Total Current Liabilities of $8.8 million as of Q3 2025, which was down 3496.37% from $3.6 million recorded in Q2 2025.
  • Serina Therapeutics' 5-year Total Current Liabilities high stood at $24.5 million for Q2 2023, and its period low was $1.4 million during Q4 2023.
  • Over the past 5 years, Serina Therapeutics' median Total Current Liabilities value was $8.8 million (recorded in 2022), while the average stood at $9.0 million.
  • As far as peak fluctuations go, Serina Therapeutics' Total Current Liabilities plummeted by 8597.94% in 2023, and later skyrocketed by 32178.53% in 2024.
  • Serina Therapeutics' Total Current Liabilities (Quarter) stood at $9.0 million in 2021, then grew by 12.39% to $10.1 million in 2022, then crashed by 85.98% to $1.4 million in 2023, then surged by 67.45% to $2.4 million in 2024, then soared by 271.47% to $8.8 million in 2025.
  • Its Total Current Liabilities stands at $8.8 million for Q3 2025, versus $3.6 million for Q2 2025 and $2.4 million for Q1 2025.